Insights from 2023 ASCO® Annual Meeting
Playback speed
10 seconds
ASCO® 2023 Insights: "Results of MOLTO, a Multicenter, Open Label, Ph2 Clinical Trial Evaluating Venetoclax, Atezolizumab, + Obinutuzumab in Richter Syndrome"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Anna Frustaci
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Anna Frustaci
30 views
June 16, 2023
Comments 0
Login to view comments.
Click here to Login
Hematology